Inotuzumab-ozogamicin/BlinatumomabNo response: case report

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2021年 / 1864卷 / 1期
关键词：
D O I：
10.1007/s40278-021-99125-7
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：195 / 195
相关论文
共 50 条
  • [41] Loss of CD22 expression and expansion of a CD22dim subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin
    Reinert, Jochim
    Beitzen-Heineke, Antonia
    Wethmar, Klaus
    Stelljes, Matthias
    Fiedler, Walter
    Schwartz, Stefan
    ANNALS OF HEMATOLOGY, 2021, 100 (11) : 2727 - 2732
  • [42] Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series*
    Brivio, Erica
    Chantrain, Christophe F.
    Gruber, Tanja A.
    Thano, Adriana
    Rialland, Fanny
    Contet, Audrey
    Elitzur, Sarah
    Dalla-Pozza, Luciano
    Kallay, Krisztian Miklos
    Li, Chi-kong
    Kato, Motohiro
    Markova, Inna
    Schmiegelow, Kjeld
    Bodmer, Nicole
    Breese, Erin H.
    Hoogendijk, Raoull
    Pieters, Rob
    Zwaan, Christian Michel
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (06) : 1172 - 1177
  • [43] INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Papayannidis, Cristina
    Zappasodi, Patrizia
    Fracchiolla, Nicola S.
    Di Raimondo, Francesco
    Mattei, Daniele Giovanni
    Lanza, Francesco
    Mauro, Endri
    Del Principe, Maria Ilaria
    Borlenghi, Erika
    Fumagalli, Monica
    Todisco, Elisabetta
    Sica, Simona
    Di Renzo, Nicola
    De Fabritiis, Paolo
    Corradini, Paolo
    Vallisa, Daniele
    Petruzziello, Fara
    Luppi, Mario
    Pane, Fabrizio
    Ferrara, Felicetto
    Passamonti, Francesco
    Mule, Antonino
    Zingaretti, Chiara
    Marconi, Giovanni
    Valli, Irene
    Petracci, Elisabetta
    Clemente, Alberto
    Saglio, Giuseppe Nicola
    Ciceri, Fabio
    Martinelli, Giovanni
    BLOOD, 2021, 138
  • [44] Loss of CD22 expression and expansion of a CD22dim subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin
    Jochim Reinert
    Antonia Beitzen-Heineke
    Klaus Wethmar
    Matthias Stelljes
    Walter Fiedler
    Stefan Schwartz
    Annals of Hematology, 2021, 100 : 2727 - 2732
  • [45] A method for optimizing dosage regimens in oncology by visualizing the safety and efficacy response surface: analysis of inotuzumab ozogamicin
    Luu, Kenneth T.
    Boni, Joseph
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (04) : 697 - 708
  • [46] Inotuzumab ozogamicinNeurological and renal toxicity: case report
    Reactions Weekly, 2019, 1745 (1) : 159 - 159
  • [47] Inotuzumab-ozogamicinThrombocytopenia: 2 case report
    Reactions Weekly, 2021, 1836 (1) : 426 - 426
  • [48] Inotuzumab-ozogamicinLiver toxicity: case report
    Reactions Weekly, 2022, 1889 (1) : 178 - 178
  • [49] Inotuzumab-ozogamicinLack of efficacy: case report
    Reactions Weekly, 2023, 1938 (1) : 746 - 746
  • [50] Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
    Kantarjian, Hagop M.
    DeAngelo, Daniel J.
    Stelljes, Matthias
    Martinelli, Giovanni
    Liedtke, Michaela
    Stock, Wendy
    Gokbuget, Nicola
    O'Brien, Susan
    Wang, Kongming
    Wang, Tao
    Paccagnella, M. Luisa
    Sleight, Barbara
    Vandendries, Erik
    Advani, Anjali S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (08): : 740 - 753
12345